BEXMAB Survival Data Remain Subgroup-Dependent
Faron Pharmaceuticals reported the first overall-survival cut from 21 treatment-naïve higher-risk MDS patients receiving bexmarilimab plus azacitidine in the Phase 1/2 BEXMAB study. After 14.9 months of median follow-up, median overall survival was not…
